Gasdermin E: A Prospective Target for Therapy of Diseases.

Front Pharmacol

School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China.

Published: April 2022

Gasdermin E (GSDME) is a member of the gasdermin protein family, which mediates programmed cell death including apoptosis and pyroptosis. Recently, it was suggested that GSDME is activated by chemotherapeutic drugs to stimulate pyroptosis of cancer cells and trigger anti-tumor immunity, which is identified as a tumor suppressor. However, GSDME-mediated pyroptosis contributes to normal tissue damage, leading to pathological inflammations. Inhibiting GSDME-mediated pyroptosis might be a potential target in ameliorating inflammatory diseases. Therefore, targeting GSDME is a promising option for the treatment of diseases in the future. In this review, we introduce the roles of GSDME-driven programmed cell death in different diseases and the potential targeted therapies of GSDME, so as to provide a foundation for future research.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019550PMC
http://dx.doi.org/10.3389/fphar.2022.855828DOI Listing

Publication Analysis

Top Keywords

programmed cell
8
cell death
8
gsdme-mediated pyroptosis
8
gasdermin prospective
4
prospective target
4
target therapy
4
diseases
4
therapy diseases
4
diseases gasdermin
4
gsdme
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!